Kliogest N

Norethisterone acetate, the active ingredient in Kliogest N, is a combined estrogen‑progestogen presented as an oral tablet for oral use. It contains both norethisterone acetate and estradiol, providing synergistic hormonal activity. It is indicated for contraception and regulation of menstrual cycles in women of reproductive age.

GNH USA supplies Kliogest N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with capabilities for bulk manufacturing, quality assurance, and regulatory compliance, and timely delivery to global markets.

Kliogest N, a combined estrogen‑progestogen oral contraceptive, is used to manage reproductive hormone‑related conditions.

Contraception: provides reliable prevention of pregnancy when taken as prescribed. Menstrual cycle regulation: helps achieve regular menstrual bleeding patterns. Management of menstrual disorders: reduces heavy menstrual bleeding and dysmenorrhea.

Like all hormonal contraceptives, Kliogest N may cause adverse reactions.

Common Side Effects: - Nausea - Breast tenderness - Headache - Spotting between periods

Serious or Rare Side Effects: - Venous thromboembolism (deep vein thrombosis, pulmonary embolism) - Arterial thrombosis (stroke, myocardial infarction) - Severe liver dysfunction or jaundice

Before prescribing Kliogest N, clinicians should consider several precautionary measures.

Cardiovascular assessment: evaluate history of thromboembolic events, hypertension, or smoking. Liver function: avoid use in patients with active liver disease or abnormal liver enzymes. Smoking status: contraindicated in women over 35 who smoke cigarettes. Medication review: assess concomitant use of strong enzyme inducers that may reduce efficacy. Store at room temperature: keep tablets in original packaging, protect from moisture and light.

Kliogest N can interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin): may markedly reduce contraceptive efficacy. - Certain antiretroviral agents (e.g., efavirenz, nevirapine): can decrease hormone levels and increase pregnancy risk. - Hormonal therapies for breast cancer (e.g., tamoxifen): may counteract contraceptive action.

Moderate Interactions (Monitor Closely): - Antibiotics and antifungals (e.g., macrolides, ketoconazole): may modestly lower hormone concentrations. - St. John’s wort: can reduce contraceptive effectiveness, requiring additional barrier methods. - Grapefruit juice: may affect hormone metabolism, warranting monitoring.